Polycab India promoters plan a ₹888 crore block deal, while Tata Steel invests ₹4,055 crore in its overseas arm TSHP. Piramal Enterprises gets NCLT nod to merge with Piramal Finance, and Lupin receives tentative US FDA approval for a generic HIV drug. Dalmia Bharat faces ED land attachment under PMLA, and Glenmark, IPCA Labs, and Newgen Software announce key pharma and IT deals. Other developments include Akzo Nobel stake sale, Birla Corp’s RCCPL winning a Telangana limestone block, and GPT Infraprojects appointing Om Tantia as Co-Chairman. Here are few stocks to watch ahead of Thursday’s trading session.
1 / 11Polycab India Ltd | Promoter entities of Polycab India are set to offload up to 0.81% of the company’s equity through a block deal worth around ₹887.6 crore, sources told CNBC-TV18. The floor price for the transaction is ₹7,300 per share, a 3.09% discount to the last traded price.
2 / 11Tata Steel | The company invests ₹4,054.66 crore in overseas arm T Steel Holdings Pte. Ltd (TSHP), acquiring 457.7 crore shares; TSHP remains a wholly owned subsidiary.
3 / 11Piramal Enterprises Ltd | The company has received NCLT approval to merge with Piramal Finance; Anand Piramal to chair Piramal Finance, while Ajay and Swati Piramal continue leading the group.
4 / 11Lupin Ltd | The drugmaker has received tentative approval from the US FDA for its generic version of an HIV drug, to be manufactured at its Nagpur facility.
5 / 11Bratia Rolmia | The company confirms ED’s provisional attachment of ₹377.26 crore land under PMLA; company says operations unaffected and will explore legal remedies.
6 / 11Glenmark Pharma | The pharma major’s subsidiary has signed an exclusive licensing deal with Hengrui Pharma for Trastuzumab Rezetecan, a next-gen HER2-targeting ADC. Glenmark will pay $18 million upfront, with milestone payments up to $1.093 billion and royalties on sales, securing rights to develop and commercialise the drug across multiple global regions.
7 / 11IPCA Labs | The pharma company has signed a technology transfer and joint development pact with US-based BioSimilar Sciences for a next-gen monoclonal antibody biosimilar targeting cancer and autoimmune diseases. The product will be developed and manufactured at BSS’s Puerto Rico facility, with the first launch eyed for 2027. Ipca will earn milestone fees and royalties on sales.
8 / 11Akzo Nobel India | The company’s promoter, Imperial Chemical Industries, sells 5% stake for ₹765 crore in a block deal; Nippon India and WF Asian Smaller Companies Fund among key buyers.
9 / 11Birla Corp | The company’s unit, RCCPL, has been named the preferred bidder for the Kanpa-Junapani limestone block in Telangana with an 87.05% revenue-sharing offer. The block spans 3.38 sq km in Adilabad district.
10 / 11Newgen Software Technologies Ltd | Newgen Software’s UK arm has signed a €4.22 million, five-year Master Service Agreement with TCS N.V, Belgium, to provide a cloud-based enterprise records management platform. The deal covers cloud hosting, software licence and implementation services, and is purely commercial in nature.
11 / 11GPT Infraprojects | The company has appointed Om Tantia as Co-Chairman effective September 24, 2025.
